Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778802 | 0.89 | KCNH2 (0.49) | CNR2KCNH2PIK3CAHPGDTSHR | |
| SCHEMBL13778782 | 0.88 | KCNH2 (0.46) | CNR2KCNH2PIK3CAHPGDTSHR | |
| SCHEMBL13778789 | 0.82 | ALDH1A1 (0.45) | HPGDTSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1684180 | 0.82 | MEN1 (0.40) | — | |
| SCHEMBL4170043 | 0.81 | CHRM1 (0.50) | HPGDTSHRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4160989 | 0.80 | MEN1 (0.41) | CNR2 | |
| SCHEMBL13778787 | 0.80 | FSCN1 (0.39) | — | |
| SCHEMBL4180431 | 0.79 | MAPT (0.45) | HPGDALDH1A1LMNA | |
| SCHEMBL13778791 | 0.79 | MMP13 (0.40) | SMN1; SMN2LMNA | |
| SCHEMBL4805325 | 0.78 | CACNB4 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| WO-2007039802-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170846-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, IMPA1, TYMP | CNR2 4856/4885KCNH2 4089/4885PIK3CA 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.